ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1162

IL37 Reduces Pro-Inflammatory Cytokine and Catabolic Enzyme Production in Human Chondrocytes: A Protective Role in Osteoarthritis?

Ellen van Geffen1, Arjan van Caam2, Elly Vitters2, Henk van Beuningen2, Esmeralda Blaney Davidson2 and Peter M. van der Kraan2, 1Experimential Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cartilage, cytokines and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, primarily characterized by progressive articular cartilage degradation. Cartilage destruction is assumed to be mediated by pro-inflammatory cytokines, including IL-1β, IL-6, IL-8 and TNFα  via induction of matrix degrading enzymes, such as matrix metalloproteinases (MMPs) and A Disintegrin-like and Metalloproteinases with Thrombospondin Motifs (ADAMTS). Recently, IL37 has come into view as an anti-inflammatory cytokine with inhibitory properties on innate immune responses by decreasing the production of pro-inflammatory cytokines. In this study we investigated  if IL37 is able to reduce the expression and secretion of pro-inflammatory cytokines and catabolic enzymes in human OA chondrocytes.

Methods: Cartilage was obtained from eight OA patients undergoing total knee or hip joint arthroplasty. First IL37 expression was analyzed by immunohistochemistry. To determine if IL37 expression is responsive to pro-inflammatory cytokines, chondrocytes were stimulated with IL-1β (10 ng/ml). IL37 gene expression was measured using qPCR. The functionality of IL37 was tested in primary human OA chondrocytes by overexpression of human IL37 via an adenovirus. Subsequently, chondrocytes were stimulated with IL-1β to create an OA-like environment. The effect of IL37 on the production and secretion of pro-inflammatory cytokines and enzymes in this environment was analyzed by qPCR, Western Blot and Luminex.

Results: In cartilage of OA patients, immunohistochemical analysis indicated that IL37 protein was indeed expressed by chondrocytes. Furthermore, we found that in primary OA chondrocytes the production of IL37 is significantly (p<0.0076) induced through IL-1β  stimulation. After overexpression, IL37 was effective to suppress IL-1β-induced gene expression of the pro-inflammatory cytokines IL-1β (p<0.0007), IL-6 (p<0.0043), IL-8 (p<0.0002) and the catabolic enzymes MMP3 (p<0.0010) and ADAMTS5 (p<0.0104) gene expression levels. In addition to gene expression analysis, we also studied the protein expression of pro-inflammatory cytokines in response to IL37 in primary OA chondrocytes. IL37 significantly reduced IL-1β-induced IL-6 (p<0.0111) and IL-8 protein (p<0.0001) levels in the supernatant of primary OA chondrocyte cultures. Furthermore, on Western blot analysis IL37 showed a reduction in IL-1β-induced IL-1β protein level.

Conclusion: In the present study, we showed basal IL37 protein expression and IL-1β- induced IL37 gene expression in human OA cartilage. This is the first study, demonstrating the enhanced expression of IL37 by primary human OA chondrocytes in an inflammatory environment. Furthermore, IL37 potently reduced the IL-1β-induced production and secretion of pro-inflammatory cytokines and catabolic enzymes. Clearly, these data implicate IL37 as a potent protective cytokine against cartilage degradation.


Disclosure: E. van Geffen, None; A. van Caam, None; E. Vitters, None; H. van Beuningen, None; E. Blaney Davidson, None; P. M. van der Kraan, None.

To cite this abstract in AMA style:

van Geffen E, van Caam A, Vitters E, van Beuningen H, Blaney Davidson E, van der Kraan PM. IL37 Reduces Pro-Inflammatory Cytokine and Catabolic Enzyme Production in Human Chondrocytes: A Protective Role in Osteoarthritis? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/il37-reduces-pro-inflammatory-cytokine-and-catabolic-enzyme-production-in-human-chondrocytes-a-protective-role-in-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il37-reduces-pro-inflammatory-cytokine-and-catabolic-enzyme-production-in-human-chondrocytes-a-protective-role-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology